Stay updated on Ixazomib Role in ASCT in Relapsed Myeloma - Clinical Trial
Sign up to get notified when there's something new on the Ixazomib Role in ASCT in Relapsed Myeloma - Clinical Trial page.

Latest updates to the Ixazomib Role in ASCT in Relapsed Myeloma - Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoChange DetectedNo substantive changes to the study record are evident; the version history shows the initial entry with the same details and the page layout remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check40 days agoChange Detected- Added a government-funding notice about potential delays and updated operating status guidance, and a major version bump to v3.2.0. - Removed the previous version tag v3.1.0.SummaryDifference13%

- Check47 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. The change is limited to the revision label; no core content or critical data appears to be altered.SummaryDifference0.3%

- Check62 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2. No other content changes are detected on the page.SummaryDifference0.3%

- Check69 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1.SummaryDifference0.3%

- Check76 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location, while several location-related terms and the previous revision number have been removed.SummaryDifference4%

Stay in the know with updates to Ixazomib Role in ASCT in Relapsed Myeloma - Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ixazomib Role in ASCT in Relapsed Myeloma - Clinical Trial page.